Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update

Abeona Therapeutics Inc (NASDAQ:ABEO) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 1,990,000 shares, a growth of 17.1% from the March 15th total of 1,700,000 shares. Based on an average trading volume of 333,800 shares, the days-to-cover ratio is presently 6.0 days. Currently, 7.7% of the company’s stock are short sold.

Insider Buying and Selling

In related news, Director Mark Alvino sold 7,084 shares of Abeona Therapeutics stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $5.11, for a total transaction of $36,199.24. Following the sale, the director now directly owns 62,816 shares in the company, valued at approximately $320,989.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.30% of the stock is owned by company insiders.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in Abeona Therapeutics by 5.2% during the third quarter. Northern Trust Corp now owns 108,647 shares of the biopharmaceutical company’s stock worth $457,000 after buying an additional 5,412 shares in the last quarter. State Street Corp boosted its holdings in Abeona Therapeutics by 18.0% during the second quarter. State Street Corp now owns 51,095 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 7,800 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in Abeona Therapeutics during the third quarter worth about $43,000. GSA Capital Partners LLP purchased a new stake in Abeona Therapeutics during the third quarter worth about $49,000. Finally, Bank of New York Mellon Corp purchased a new stake in Abeona Therapeutics during the second quarter worth about $52,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday.

Abeona Therapeutics Stock Up 1.2 %

Shares of NASDAQ:ABEO opened at $7.64 on Tuesday. The company has a market cap of $208.99 million, a price-to-earnings ratio of -2.96 and a beta of 1.49. The firm’s 50-day simple moving average is $7.27 and its 200-day simple moving average is $5.53. Abeona Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, research analysts forecast that Abeona Therapeutics will post -1.83 EPS for the current year.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.